Response to Comment on Rosenstock et al. Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial. Diabetes Care 2020;43:2509–2518

Abstract

I thank Dr. Marathe and coauthors, who are part of the superb team of Michael Horowitz and Karen Jones, world-renowned top experts in gastric emptying (1), for recognizing the clinical value of our albiglutide switch study (HARMONY 8), which provided proof of concept for the benefits of using a weekly glucagon-like peptide 1 receptor agonist (GLP-1RA) to simplify an intensive multiple-insulin regimen in patients with long-standing type 2 diabetes previously on basal-bolus insulin (2). We clearly demonstrated that 54% of participants randomized to the albiglutide + basal insulin glargine group were able to replace all prandial insulin without reintroducing insulin lispro, and, for those who still needed prandial insulin, their insulin doses were substantially …